Post Finasteride Syndrome: Demographics from FDA Database

This document reports on a study of post-finasteride syndrome (PFS), a cluster of symptoms associated with exposure to 5-alpha reductase inhibitors (5ARI). The study analyzed 3,295 cases reported to the FDA between April 2011 and October 2014, and found that cases were most often reported by patients rather than healthcare professionals. Finasteride 1mg was associated with PFS-like symptoms in a younger population with a median age of 35, compared to finasteride 5mg which had a median age of 61. The study concludes that further exploration is needed to understand the true existence, cause(s), and mechanism of action of PFS.